Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M125,930Revenue $M34,858Net Margin (%)12.0Z-Score2.2
Enterprise Value $M171,070EPS $1.7Operating Margin %15.6F-Score5
P/E(ttm))27.6Cash Flow Per Share $0Pre-tax Margin (%)12.9Higher ROA y-yN
Price/Book19.710-y EBITDA Growth Rate %0.5Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.35-y EBITDA Growth Rate %-5.1Current Ratio1.1Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-43.6ROA % (ttm)6.8Higher Current Ratio y-yN
Dividend Yield %5.5Insider Buy (3m)0ROE % (ttm)47.5Less Shares Outstanding y-yY
Payout Ratio %141Shares Outstanding M2,678ROI % (ttm)14.0Gross Margin Increase y-yY

Gurus Latest Trades with GSK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKDodge & Cox 2014-12-31 Reduce-0.64%$41.3 - $47.14
($44.76)
$ 47.005%Reduce -37.91%23,959,301
GSKHOTCHKIS & WILEY 2014-12-31 Add0.21%$41.3 - $47.14
($44.76)
$ 47.005%Add 13.04%12,213,885
GSKDavid Dreman 2014-12-31 Sold Out -0.01%$41.3 - $47.14
($44.77)
$ 47.005%Sold Out0
GSKDodge & Cox 2014-09-30 Reduce-1.11%$46.29 - $54.52
($49.01)
$ 47.00-4%Reduce -35.93%38,589,161
GSKHOTCHKIS & WILEY 2014-09-30 Add0.98%$46.29 - $54.52
($49.01)
$ 47.00-4%Add 118.31%10,804,564
GSKCharles Brandes 2014-09-30 Add0.56%$46.29 - $54.52
($49.01)
$ 47.00-4%Add 36.63%3,415,717
GSKIrving Kahn 2014-09-30 Buy 0.38%$46.29 - $54.52
($49.01)
$ 47.00-4%New holding51,000
GSKNWQ Managers 2014-09-30 Add0.03%$46.29 - $54.52
($49.01)
$ 47.00-4%Add 39.82%208,125
GSKDavid Dreman 2014-09-30 Buy 0.01%$46.29 - $54.52
($49.01)
$ 47.00-4%New holding1,328
GSKHOTCHKIS & WILEY 2014-06-30 Add0.93%$51.55 - $56.39
($54.16)
$ 47.00-15%Add 13358.60%4,949,118
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 47.00-15%Add 15.52%2,500,048
GSKJohn Rogers 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 47.00-15%Add 49.33%988,772
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 47.00-15%New holding270,900
GSKJohn Rogers 2014-03-31 Add0.16%$50.9 - $56.66
($54.07)
$ 47.00-15%Add 57.21%662,150
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 47.00-15%Sold Out0
GSKNWQ Managers 2014-03-31 Reduce-0.03%$50.9 - $56.66
($54.07)
$ 47.00-15%Reduce -28.91%148,800
GSKHOTCHKIS & WILEY 2014-03-31 Buy 0.01%$50.9 - $56.66
($54.07)
$ 47.00-15%New holding36,773
GSKJohn Rogers 2013-12-31 Add0.19%$49.31 - $53.68
($51.87)
$ 47.00-10%Add 208.93%421,201
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 47.00-10%Add 13.11%2,145,461
GSKVanguard Health Care Fund 2013-12-31 Reduce-0.14%$49.31 - $53.68
($51.87)
$ 47.00-10%Reduce -55.18%644,881
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$22110.5view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14119.06view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29775.43view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12285.92view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14230.79view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12285.92view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      Taking a Closer Look at GlaxoSmithKline Apr 22 2015 
      British Stock Picks From Gurus During Q4 Mar 24 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Bestinfond Adds More Than a Dozen Foreign Stocks to Portfolio Mar 06 2015 
      Causeway International Value Fund Adds 2 New Stocks Mar 03 2015 
      Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
      Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
      Bestinfond's Top 5 New Buys During Q4 Feb 03 2015 
      Can GlaxoSmithKline Continue Striving in the Face of World Challenges? Jan 30 2015 
      Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 


      More From Other Websites
      World's first malaria vaccine moves closer to use in Africa Apr 23 2015
      Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog Apr 23 2015
      Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc? Apr 23 2015
      Novartis keeps full-year target as Q1 earnings fall Apr 23 2015
      AQR Capital More Than Doubles its Holdings in Gilead Sciences Apr 23 2015
      Novartis (NVS) Beats on Earnings & Revenues - Tale of the Tape Apr 23 2015
      Divestment gains boost net earnings at drug company Novartis Apr 23 2015
      Divestment gains boost net earnings at drug company Novartis Apr 23 2015
      Novartis Profit Boosted Disposals Apr 23 2015
      Novartis keeps full-year target as Q1 earnings fall Apr 22 2015
      Tate & Lyle slides as analyst turns negative Apr 22 2015
      According To This Fund Manager, GlaxoSmithKline plc Is A Tremendous Opportunity Right Now! Apr 22 2015
      Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog Apr 21 2015
      3 Stocks To Ride Out Mayhem In May: British American Tobacco plc, GlaxoSmithKline plc And Unilever... Apr 21 2015
      BioMed Realty, L.P. -- Moody's upgrades BioMed's senior unsecured ratings to Baa2; outlook is stable Apr 20 2015
      5 Reasons Why Dividends Are Back: BHP Billiton plc, BP plc, GlaxoSmithKline plc, Rio Tinto plc &... Apr 20 2015
      Veeva's Latest Solution to Ease Medical Product Rollouts - Analyst Blog Apr 17 2015
      Pfizer Wins First Trial Over Zoloft Birth-Defect Claims Apr 17 2015
      Glaxo recalls flu vaccine due to potency problem Apr 17 2015
      Glaxo recalls flu vaccine due to potency problem Apr 17 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK